Cellectar Biosciences, Inc. (CLRB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Cellectar Biosciences, Inc. (CLRB) is down 12.9% since the beginning of the year. At $3 per share, CLRB is trading 60.6% below its 52-week high of $7. Investors who bought $1,000 worth of CLRB shares 5 years ago would now be looking at an investment worth $8.

Cellectar Biosciences, Inc. (CLRB) has returned -12.88% so far this year and -45.55% over the past 12 months. Over the last ten years, CLRB has returned -55.04% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.

Based on dividend-adjusted daily data since Nov 10, 2005, CLRB's average daily return is -0.08%, while the average monthly return is -3.42%.

Historically, 37% of months were positive and 63% were negative. The best month was Dec 2009 with a return of +234.2%, while the worst month was Feb 2010 at -87.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.

On a daily basis, CLRB closed higher 38% of trading days. The best single day was May 20, 2016 with a return of +228.6%, while the worst single day was Feb 24, 2010 at -80.8%.

Cellectar Biosciences, Inc. has an annualized alpha of -22.79%, beta of 0.60, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 10, 2005.

• This stock participated in 208.46% of S&P 500 Index downside but only -95.21% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.60 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CLRB ranks 19 for risk / return — above 19% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cellectar Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cellectar Biosciences, Inc. was 100.00%, occurring on Jun 12, 2026. The portfolio has not yet recovered.

The current Cellectar Biosciences, Inc. drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cellectar Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cellectar Biosciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.